Better Asthma Treatment: Monitoring with ACT and Nitric oxide.
Completed
- Conditions
- Asthma control, monitoring, children, exhaled nitric oxide
- Registration Number
- NL-OMON26506
- Lead Sponsor
- Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
1. Children 4-18 years old with allergic asthma, using inhaled corticosteroids for at least 3 months preceding the study;
2. Children and/or their parents should have access to the Internet at home;
Exclusion Criteria
1. Active smoking;
2. Chronic lung disease other than asthma;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is the proportion of symptom free days (SFD) during the 4 weeks before the final visit (t =12 months).
- Secondary Outcome Measures
Name Time Method Secondary endpoints are:<br /><br>1. Daily and nocturnal symptoms, limitation of activities, use of rescue and controller medication as assessed with diary cards during the 4 weeks before visit t = 12 months;<br /> <br>2. Asthma related quality of life assessed with the PAQLQ;<br /><br>3. Compliance with treatment during the 4 weeks before visit t=12 months, as assessed by diary cards and pharmacy data;<br /><br>4. Airway hyperresponsiveness (PD20 methacholine);<br /><br>5. FENO;<br /><br>6. Spirometry (FEV1, FEF25%);<br /><br>7. Exacerbations: unscheduled doctor visits related to asthma, systemic steroid courses, emergency room visits and hospital admissions all related to asthma;<br /><br>8. ICS dose;<br /><br>9. Patient utilities (EQ-5D);<br /><br>10. Costs (CostQ).<br>